GSK plc (ticker: GSK, GSK.L) has announced that the European Commission has granted approval for Jemperli in combination with chemotherapy as a first-line treatment. This is intended for adult patients with both primary advanced and recurrent endometrial cancer who are eligible for systemic therapy. The approval extends the previous indication for using Jemperli alongside chemotherapy within the EU, now including patients with mismatch repair proficient or microsatellite stable tumors.
The company also highlighted that in August 2024, the US label for Jemperli plus chemotherapy was expanded to cover all adult patients with both primary advanced and recurrent endometrial cancer.
